Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach... Show more
On April 11, 2025, the Stochastic Oscillator for CRON moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 78 instances where the indicator left the oversold zone. In of the 78 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRON's RSI Indicator exited the oversold zone, of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CRON just turned positive on April 15, 2025. Looking at past instances where CRON's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .
CRON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on March 13, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CRON as a result. In of 110 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 10-day moving average for CRON crossed bearishly below the 50-day moving average on March 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CRON entered a downward trend on April 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.912) is normal, around the industry mean (60.843). P/E Ratio (0.000) is within average values for comparable stocks, (89.540). CRON's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.913). Dividend Yield (0.000) settles around the average of (0.120) among similar stocks. P/S Ratio (11.481) is also within normal values, averaging (20.019).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CRON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
pharmaceutical, medical marijuana, cannabis
Industry PharmaceuticalsOther
A.I.dvisor indicates that over the last year, CRON has been loosely correlated with TLRY. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if CRON jumps, then TLRY could also see price increases.
Ticker / NAME | Correlation To CRON | 1D Price Change % | ||
---|---|---|---|---|
CRON | 100% | N/A | ||
TLRY - CRON | 65% Loosely correlated | -5.42% | ||
CGC - CRON | 65% Loosely correlated | +0.85% | ||
ACB - CRON | 65% Loosely correlated | +2.30% | ||
OGI - CRON | 62% Loosely correlated | +2.88% | ||
CRDL - CRON | 30% Poorly correlated | N/A | ||
More |